PIR International Supports Appointment of Chief Business Officer at CHARM Therapeutics
CHARM Therapeutics is a protein-ligand intelligence company turning advanced protein-ligand prediction into impactful medicines. CHARM’s advanced protein-ligand prediction platform, DragonFold, provides unique 3D insights into the dynamic structure of the protein-ligand binding interactions, with the potential for profound impacts on the design of novel molecules and delivery of new medicines. The Company’s initial focus is novel small molecules to treat cancer, but the technology is potentially applicable to many other therapeutic areas. CHARM is based in Cambridge and London and has raised $70 million to date, supported by high quality international investors including OrbiMed, F-Prime Capital, General Catalyst, Khosla Ventures, Bristol Myers Squibb, NVIDIA and Grep VC.
CHARM entrusted the team at PIR International to find them a highly experienced Chief Business Officer who could lead business development and drive strategic value from CHARM’s leading protein-ligand intelligence platform. After a thorough and detailed search carried out by Tom Bradley, Sally Hope and Paul Hoey of PIR International, CHARM appointed Beverley Carr to fulfil this crucial role for the organisation.
Beverley Carr, Chief Business Officer of CHARM Therapeutics, stated:
The PIR team played a key role in supporting me in the transition to my role as Chief Business Officer at CHARM Therapeutics and were responsive and highly attentive. I look forward to working alongside the team to contribute to the company’s development and long-term success.
CHARM Therapeutics, commented:
“The team at PIR International act with the highest levels of professionalism, able to manage their stakeholders in a collaborative and insightful way. They are adept at understanding a company’s culture and requirements whilst bringing new insights to the table to help overcome inevitable challenges in finding the right candidate."
